Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor, which is the main receptor responsible for ADP-induced platelet aggregation. It functions by directly changing the conformation of the P2Y12 receptor to inhibit ADP binding. Ticagrelor has been studied for its application in antiplatelet therapy to prevent ischemic cardiac complications associated with cardiovascular diseases.
API's & Drug Standards
Send us your enquiry for Ticagrelor. We offer custom pack sizes at special prices. We aim to respond to your enquiry within 24 hours.
We value your input so if you have suggestions regarding new applications for Ticagrelor email us and we will include your contribution on the website.